I think this is likely an opportunity like the one offered by $MU in 2016 when I last published a long term chart about it. We may have a huge long term bottom at hand here.
I'm already in this position, but it's viable to start accumulating shares here, as this will be a lengthy long term advance if I'm correctly diagnosing it, downside risk is minimal.
Valuation...
I dislike Pharma as much as I dislike manipulation but GILD bounced off .618 fib and I like it. Seems like a $65-70 stock trading at a discount.
Solid 4.8% DIV yield in addition.
Dont forget these folks also have anti Rona stuff so it could all come together.
Gilead activated a double bottom pattern with target at $104.6, +84% from current price. This structure would be inactivated below $55.80 so the stop loss would be around that zone. The risk/reward ratio is 45.
FDA provides preliminary approval for the drug filgotinib not approved, Galapagos will now assume full responsibility for filgotinib in Europe. Gilead will pay EUR 160 million to Galapagos to accelerate commercial activities in Europe. The gap from 19 march 2019 is filled....ready for the turn up..... what do you think?
I like this chart a lot actually. if we bounce off this crossroad, we will reach the moon eventually. Adding a little to my long position.
Have a terrific weekend!
EN: Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California, that researches, develops and markets drugs in under-explored areas of medical need in the United States, Europe, and
internationally. Its products include treatments for human immunodeficiency virus (HIV) infection and liver disease.
It is currently...
Wonderful bullish news! There is a vaccine. The economic activity can soon go back to normal. The question now is how do we make it obligatory?
Crazy antivax conspiracy theorists are saying that because it is a rushed & untested vaccine and entirely new technology that affects ARN and contains heavy metals that can breach the blood-brain barrier we should let...
Reuters
Adage Capital Partners GP LLC Dissolves Share Stake In Moderna, Takes In Gilead Sciences!
Reuters:
Germany requests 5% of EU supply of remdesivir
Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the...
We maybe have finished movement inside this monthly downward channel, which looks like a corrective channel for previous bullish impulse. Chances are we will go north from here. But if price will brake this channel downwards it may as well become ugly, and there is no support levels, I guess?
Anyway, now GILD highly tightened to SNP and thus electional uncertainty.
NASDAQ:GILD
Based on technical analysis, the idea is to go long only if the bottom support level of 60 USD will not be broken.
Target prices are:
1. 68USD
2. 80 USD
I also wrote on the huge upside potential of Gilead when they acquired Immunomedics for $21 billion.
The acquisition expands Gilead's portfolio of treatments for various types of cancer.
On 9/10/2020 Oppenheimer Brokerage Boosted Price Target to Outperform from...
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
The deal with Immunomedics provides Gilead (GILD) with Trodelvy, an antibody drug for advanced triple-negative breast cancer. The drug was given accelerated FDA approval in April. (Source CNN Business).
Sell on 1 hour chart
Buy on 7h chart
Sell on 3 day chart, but a trend...
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure...
Hearing chatter down the grape vine about Remdesivir again, watch for the bounce back-up on GILD. This was just trading in the $80 dollar range so keep an eye out for that move on the news.
